Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis
NCT01173159 is an interventional trial sponsored by Children's Hospital Medical Center, Cincinnati. As of 21 Nov 2026, it is completed. It studies Omegaven in Cholestasis. The registry lists an enrollment of 10 participants at 1 site in 1 country. The registry lists a start date of 31 Jul 2010 and a primary completion date of 31 Dec 2018.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01173159 |
| Status | Completed |
| Study type | Interventional trial |
| Lead sponsor | Children's Hospital Medical Center, Cincinnati |
| Enrollment | 10 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Cholestasis |
| Drugs | Omegaven |
| Start | 31 Jul 2010 |
| Primary completion | 31 Dec 2018 |
| Study completion | 31 Dec 2018 |
| Last update posted | 17 Jun 2020 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Samuel Kocoshis, MD
Children's Hospital Medical Center, Cincinnati
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cincinnati Children's Hospital Medical Center
Cincinnati
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01173159
Each answer restates registry values shown on this page.
What is NCT01173159?
NCT01173159 is an interventional trial sponsored by Children's Hospital Medical Center, Cincinnati. It studies Omegaven in Cholestasis.
Who leads NCT01173159?
The registry names Samuel Kocoshis, MD (principal investigator, Children's Hospital Medical Center, Cincinnati) as the overall official.
Where does NCT01173159 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01173159 study?
The registered drug and biological interventions are Omegaven.
When did NCT01173159 end?
The registry lists a primary completion date of 31 Dec 2018 and a study completion date of 31 Dec 2018. The sponsor last updated the record on 17 Jun 2020.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.